CancerDrs

Prostate Cancer clinical trials in Idaho

7 actively recruiting prostate cancer trials at 9 sites across Idaho.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Idaho:
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
  • Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
  • Saint Luke's Cancer Institute - Nampa — Nampa, Idaho
Phase 3 Recruiting Academic/Other

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Idaho:
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
  • Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho
Phase 2 Recruiting Academic/Other

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Idaho:
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Idaho:
  • Massive Bio SYNERGY-AI site — Boise, Idaho
Recruiting Industry

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

The study is a prospective, multi-center, single cohort study involving up to 10 urological clinics in the US. After provision of informed consent, up to 20 mL of whole blood will be collected from each subject. The samples will be blinded…

Sponsor: Sequenom, Inc.
NCT ID: NCT07543757
Sites in Idaho:
  • Idaho Urologic Institute — Meridian, Idaho

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12